| Species |
Human |
| Protein Construction |
GRO-α (Ala35-Asn107)
Accession # P09341 |
|
| Purity |
> 97% as analyzed by SDS-PAGE
> 97% as analyzed by HPLC |
| Endotoxin Level |
< 1 EU/μg of protein by LAL method |
| Biological Activity |
Fully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using human peripheral blood neutrophils is in a concentration range of 10.0-50.0 ng/ml. |
| Expression System |
E. coli |
| Theoretical Molecular Weight |
7.9 kDa |
| Formulation |
Lyophilized from a 0.2 μm filtered solution in 20 mM PB, pH 7.4, 150 mM NaCl. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
| Target Background |
GRO-α/MGSA/CXCL1 has chemotactic activity for neutrophils. It may play a role in inflammation and exerts its effects on endothelial cells in an autocrine fashion. All three isoforms of GRO are CXC chemokines that can signal through the CXCR1 or CXCR2 receptors. GRO expression is inducible by serum or PDGF and/or by a variety of inflammatory mediators, such as IL-1 and TNF, in monocytes, fibroblasts, melanocytes and epithelial cells. In certain tumor cell lines, GRO is expressed constitutively. |
| Synonyms |
Growth Regulated Protein/Melanoma Growth Stimulatory Activity; GRO α; MGSA α; CXCL1; NAP-3; GRO1; KC (murine); CINC (rat) |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
